Show simple item record

AuthorMehta, Khyati Y.
AuthorWu, Hung-Jen
AuthorMenon, Smrithi S.
AuthorFallah, Yassi
AuthorZhong, Xiaogang
AuthorRizk, Nasser
AuthorUnger, Keith
AuthorMapstone, Mark
AuthorFiandaca, Massimo S.
AuthorFederoff, Howard J.
AuthorCheema, Amrita K.
Available date2017-10-04T10:22:06Z
Publication Date2017-09-15
Publication NameOncotargeten_US
Identifierhttp://dx.doi.org/10.18632/oncotarget.20324
CitationKhyati Y. Mehta, Hung-Jen Wu, Smrithi S. Menon, Yassi Fallah, Xiaogang Zhong, Nasser Rizk, Keith Unger, Mark Mapstone, Massimo S. Fiandaca, Howard J. Federoff, and Amrita K. Cheema. "Metabolomic biomarkers of pancreatic cancer: a meta-analysis study" Oncotarget (2017) volume 8, issue 40, pp. 68899-68915
URIhttp://hdl.handle.net/10576/5666
AbstractPancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is no blood test for early detection and diagnosis of this disease. Several research groups have reported on metabolomics based clinical investigations to identify biomarkers of PC, however there is a lack of a centralized metabolite biomarker repository that can be used for meta-analysis and biomarker validation. Furthermore, since the incidence of PC is associated with metabolic syndrome and Type 2 diabetes mellitus (T2DM), there is a need to uncouple these common metabolic dysregulations that may otherwise diminish the clinical utility of metabolomic biosignatures. Here, we attempted to externally replicate proposed metabolite biomarkers of PC reported by several other groups in an independent group of PC subjects. Our study design included a T2DM cohort that was used as a non-cancer control and a separate cohort diagnosed with colorectal cancer (CRC), as a cancer disease control to eliminate possible generic biomarkers of cancer. We used targeted mass spectrometry for quantitation of literature-curated metabolite markers and identified a biomarker panel that discriminates between normal controls (NC) and PC patients with high accuracy. Further evaluation of our model with CRC, however, showed a drop in specificity for the PC biomarker panel. Taken together, our study underscores the need for a more robust study design for cancer biomarker studies so as to maximize the translational value and clinical implementation.
SponsorThis work was supported by ACS IRG-92-152-17 pilot award number AWD4470404 to KU and AKC. The authors would like to acknowledge the Metabolomics Shared Resource in Georgetown University (Washington DC, USA) partially supported by NIH/NCI/CCSG grant P30-CA051008
Languageen
PublisherImpact Journals
Subjectpancreatic cancer
SubjectMetabolomic
Subjectbiomarkers
TitleMetabolomic biomarkers of pancreatic cancer: a meta-analysis study
TypeArticle
Pagination68899-68915
Issue Number40
Volume Number8
ESSN1949-2553


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record